HUTCHMED (China) (HCM) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 495.3% versus a loss of 10.6%. Over five years, SLS leads with a +28.1% price change compared with -55.8% for HCM. HUTCHMED (China) is the larger company by market cap ($2.37 billion vs $2.19 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | SLS |
|---|---|---|
| Share price | $13.62 | $10.84 |
| Market cap | $2.37B | $2.19B |
| 1-day change | -4.66% | -4.16% |
| YTD return | +7.13% | +200.00% |
| 1-year return | -10.64% | +495.26% |
| 5-year return | -55.79% | +28.09% |
| P/E ratio (TTM) | 136.15 | — |
| Forward P/E | 52.52 | — |
| EPS (TTM) | $0.10 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | — |
| Revenue growth (YoY) | -12.96% | — |
| Net income (latest FY) | $456.91M | — |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | — |
| Net margin | 83.30% | — |
| 52-week high | $16.33 | $15.88 |
| 52-week low | $9.77 | $1.39 |
| Distance from 52-week high | -16.63% | -31.74% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +61.66% | +199.82% |
| Average volume | 67.70K | 6.56M |
| Shares outstanding | 173.81M | 201.95M |
| Employees | 1,790 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed HCM by 505.9 percentage points over the past year.
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
HCM vs SLS FAQ
Which is bigger, HUTCHMED (China) or SELLAS Life Sciences Group?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.37B compared with $2.19B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, HCM or SLS?
SLS returned +495.26% over the past 12 months, compared with -10.64% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.